Synopsis
Identify medicines whose current harms or burdens exceed likely benefit, agree priorities with the person and carry out monitored withdrawal without avoidable destabilisation.
- Polypharmacy is a reason to examine the regimen; medicine count alone does not determine appropriateness.
- Confirm what each medicine is for and whether the original indication still applies.
- Look for prescribing cascades, duplicate mechanisms, withdrawal risk and medicines continued after a temporary indication ended.
Reasoning priorities
Determine the contribution expected from every current medicine.
Link each item to a documented diagnosis or symptom and ask whether a meaningful benefit was ever observed. For preventive treatment, examine the person’s baseline risk and time horizon. Absence of symptoms does not prove a preventive medicine is unnecessary, while a long prescription history does not prove continuing value.
Worked reasoning
An 84-year-old takes twelve medicines and wants to feel less sleepy and manage fewer administration times. The list includes nightly zopiclone used for years, omeprazole started with an NSAID that ended months ago, and indicated secondary-prevention treatment after myocardial infarction.
- Clarify the goals and reconstruct the indications. Ask about current dyspepsia, previous ulcer or bleeding, ongoing antithrombotic treatment and other reasons for gastroprotection. The historical link to an NSAID is a lead to investigate, not sufficient evidence by itself to stop omeprazole.
- Assess the sleep medicine’s actual benefit, daytime sedation, falls and previous reduction attempts. Explain that long exposure can produce withdrawal and that abrupt cessation would be a poor way to test whether it contributes to the current sleepiness.
- Agree a sequence that can be evaluated. If there is no continuing indication for acid suppression after full review, discuss a step-down or withdrawal trial with a symptom plan. In parallel, prepare a gradual, individually specified zopiclone reduction rather than changing every medicine at once.
- Preserve cardiovascular treatment unless its own benefit–harm review supports a change. The number twelve is not a target to reduce indiscriminately. Document what was considered, what was agreed and why some medicines remain worthwhile.
- Verify progress at planned follow-up using alertness, falls, sleep and upper gastrointestinal symptoms. Check actual doses and supply. If symptoms emerge, decide whether they represent withdrawal, rebound or the underlying disorder before reversing the entire plan.